Skip to main content
AAPL+0.69%MSFT+0.96%GOOGL-2.70%NVDA+3.63%AMZN+1.69%SPCX-7.69%TSM-9.36%AVGO-12.19%META+1.21%TSLA+1.46%LLY-0.30%WMT+1.52%JPM-2.98%BRK-B-0.36%V-0.09%SKHY-13.11%AMD-13.25%MU+2.48%XOM+0.67%JNJ+1.25%MA-0.06%ABBV+0.94%ASMLa-9.33%COST+0.76%1398.HK+0.25%KO+0.94%CVX+0.91%0700.HK-1.26%PG+0.91%CSCO-4.29%0939.HK0.00%HD+0.72%3988.HK-1.13%1816.HK+3.45%BAC-3.15%GE-2.87%0857.HK-0.49%ORCL-8.48%UNH+2.85%1288.HK-0.45%PM-1.26%0005.HK-3.08%NVS-0.50%HSBA.L-3.62%INTC-7.97%AZN-0.60%MS-5.32%RTX-1.58%ORp-0.36%TM-1.65%GBPTRY+0.41%GBPHKD+0.32%GBPMXN-0.28%USDILS+0.16%USDTRY+0.14%AUDCHF+0.13%AUDJPY+0.10%AUDUSD+0.09%AUDCAD+0.09%GBPCHF+0.08%EURCHF+0.08%GBPUSD+0.07%NZDCHF+0.06%EURJPY+0.06%GBPJPY+0.06%GBPCAD+0.05%NZDUSD+0.05%NZDJPY+0.05%NZDCAD+0.04%GBPAUD-0.04%EURUSD+0.04%EURAUD-0.04%USDCOP-0.04%AUDNZD+0.03%EURCAD+0.03%CADJPY+0.03%GBPNZD+0.02%CHFJPY+0.02%CADCHF+0.02%EURNZD-0.01%USDCHF+0.01%USDCNH+0.01%USDHKD-0.01%USDTHB-0.01%USDJPY0.00%USDCAD0.00%EURGBP0.00%USDMXN0.00%USDNOK0.00%PLNJPY0.00%GBPSGD0.00%NZDMXN0.00%USDSEK0.00%EURHKD0.00%EURDKK0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%EURSGD0.00%AUDDKK0.00%CHFSEK0.00%USDSGD0.00%EURNOK0.00%CHFNOK0.00%NZDSGD0.00%EURCZK0.00%NOKJPY0.00%USDDKK0.00%CHFSGD0.00%SGDJPY0.00%AUDSGD0.00%EURSEK0.00%EURPLN0.00%USDPLN0.00%USDZAR0.00%GBPZAR0.00%GAGUSD0.00%W10.00%XAGUSD0.00%HG10.00%S10.00%C10.00%XNGUSD0.00%USOIL0.00%XAUUSD0.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD+1.49%ETHUSD+71.01%USDTUSD+0.11%XRPUSD+61.26%SOLUSD+68.72%TRXUSDT+0.30%ZECUSDT+1.59%XMRUSDT+0.52%DOGEUSD+69.80%LINKUSD+2.12%XLMUSD-1.42%BCHUSDT-0.55%LTCUSD+68.40%UNIUSD-1.53%TONUSD+79.92%SUIUSD+0.85%HBARUSDT-0.28%TAOUSDT+2.12%AAVEUSD+0.15%ONDOUSDT+0.23%DOTUSDT+0.69%ICPUSDT+2.05%WLDUSDT+3.76%ARBUSDT+0.82%ATOMUSDT+0.44%INJUSDT+3.64%STXUSDT+1.79%PYTHUSDT+4.83%TIAUSDT+2.13%FETUSDT-1.73%SEIUSDT+0.59%JUPUSDT+2.33%GRTUSDT+0.25%OPUSDT+0.13%IOTAUSDT+1.28%POLUSDT+0.39%WIFUSDT+1.51%AXSUSDT-0.47%EOSUSDT+0.14%IMXUSDT-1.06%FARTCOINUSDT+0.19%GALAUSDT+2.69%DYDXUSDT-0.55%ORDIUSDT+1.47%NOTUSDT+1.19%RONINUSDT-0.96%AAPL+0.69%MSFT+0.96%GOOGL-2.70%NVDA+3.63%AMZN+1.69%SPCX-7.69%TSM-9.36%AVGO-12.19%META+1.21%TSLA+1.46%LLY-0.30%WMT+1.52%JPM-2.98%BRK-B-0.36%V-0.09%SKHY-13.11%AMD-13.25%MU+2.48%XOM+0.67%JNJ+1.25%MA-0.06%ABBV+0.94%ASMLa-9.33%COST+0.76%1398.HK+0.25%KO+0.94%CVX+0.91%0700.HK-1.26%PG+0.91%CSCO-4.29%0939.HK0.00%HD+0.72%3988.HK-1.13%1816.HK+3.45%BAC-3.15%GE-2.87%0857.HK-0.49%ORCL-8.48%UNH+2.85%1288.HK-0.45%PM-1.26%0005.HK-3.08%NVS-0.50%HSBA.L-3.62%INTC-7.97%AZN-0.60%MS-5.32%RTX-1.58%ORp-0.36%TM-1.65%GBPTRY+0.41%GBPHKD+0.32%GBPMXN-0.28%USDILS+0.16%USDTRY+0.14%AUDCHF+0.13%AUDJPY+0.10%AUDUSD+0.09%AUDCAD+0.09%GBPCHF+0.08%EURCHF+0.08%GBPUSD+0.07%NZDCHF+0.06%EURJPY+0.06%GBPJPY+0.06%GBPCAD+0.05%NZDUSD+0.05%NZDJPY+0.05%NZDCAD+0.04%GBPAUD-0.04%EURUSD+0.04%EURAUD-0.04%USDCOP-0.04%AUDNZD+0.03%EURCAD+0.03%CADJPY+0.03%GBPNZD+0.02%CHFJPY+0.02%CADCHF+0.02%EURNZD-0.01%USDCHF+0.01%USDCNH+0.01%USDHKD-0.01%USDTHB-0.01%USDJPY0.00%USDCAD0.00%EURGBP0.00%USDMXN0.00%USDNOK0.00%PLNJPY0.00%GBPSGD0.00%NZDMXN0.00%USDSEK0.00%EURHKD0.00%EURDKK0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%EURSGD0.00%AUDDKK0.00%CHFSEK0.00%USDSGD0.00%EURNOK0.00%CHFNOK0.00%NZDSGD0.00%EURCZK0.00%NOKJPY0.00%USDDKK0.00%CHFSGD0.00%SGDJPY0.00%AUDSGD0.00%EURSEK0.00%EURPLN0.00%USDPLN0.00%USDZAR0.00%GBPZAR0.00%GAGUSD0.00%W10.00%XAGUSD0.00%HG10.00%S10.00%C10.00%XNGUSD0.00%USOIL0.00%XAUUSD0.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD+1.49%ETHUSD+71.01%USDTUSD+0.11%XRPUSD+61.26%SOLUSD+68.72%TRXUSDT+0.30%ZECUSDT+1.59%XMRUSDT+0.52%DOGEUSD+69.80%LINKUSD+2.12%XLMUSD-1.42%BCHUSDT-0.55%LTCUSD+68.40%UNIUSD-1.53%TONUSD+79.92%SUIUSD+0.85%HBARUSDT-0.28%TAOUSDT+2.12%AAVEUSD+0.15%ONDOUSDT+0.23%DOTUSDT+0.69%ICPUSDT+2.05%WLDUSDT+3.76%ARBUSDT+0.82%ATOMUSDT+0.44%INJUSDT+3.64%STXUSDT+1.79%PYTHUSDT+4.83%TIAUSDT+2.13%FETUSDT-1.73%SEIUSDT+0.59%JUPUSDT+2.33%GRTUSDT+0.25%OPUSDT+0.13%IOTAUSDT+1.28%POLUSDT+0.39%WIFUSDT+1.51%AXSUSDT-0.47%EOSUSDT+0.14%IMXUSDT-1.06%FARTCOINUSDT+0.19%GALAUSDT+2.69%DYDXUSDT-0.55%ORDIUSDT+1.47%NOTUSDT+1.19%RONINUSDT-0.96%

FDA clears new Imfinzi bladder cancer use

NEWS

November 14, 2026 at 00:41 UTC

3 min read
Unbranded IV cancer treatment setup in a modern hospital oncology unit after new FDA bladder cancer approval

Key Points

  • 01FDA approves Imfinzi plus enfortumab vedotin for cisplatin‑ineligible muscle‑invasive bladder cancer
  • 02VOLGA Phase III trial shows 49% cut in risk of recurrence, progression, surgery failure or death
  • 03Regimen reduces risk of death by 42% versus surgery with or without adjuvant therapy
  • 04Two‑year event‑free and overall survival rates improved with manageable safety profile

FDA approval of new perioperative Imfinzi regimen

The FDA has approved AstraZeneca’s Imfinzi (durvalumab) in combination with enfortumab vedotin-ejfv as a perioperative treatment for adult patients with muscle-invasive bladder cancer who are ineligible for or have refused cisplatin-based chemotherapy. Patients receive three cycles of Imfinzi plus enfortumab vedotin before radical cystectomy, followed by Imfinzi monotherapy as adjuvant treatment after surgery.

This decision provides a new treatment option for a patient group that cannot receive standard cisplatin-based chemotherapy. The approval follows a Priority Review process and establishes a novel immunotherapy-based regimen built around Imfinzi for muscle-invasive bladder cancer.

Efficacy results from the VOLGA Phase III trial

The approval is supported by the Phase III VOLGA trial, which evaluated perioperative Imfinzi with neoadjuvant enfortumab vedotin in patients undergoing radical cystectomy. In an interim analysis, the combination reduced the risk of disease progression, recurrence, failure to undergo surgery or death by 49% compared with radical cystectomy with or without approved adjuvant treatment, based on an event-free survival hazard ratio of 0.51.

Estimated median event-free survival had not been reached for patients treated with the Imfinzi combination, versus 12.1 months for the comparator arm. At two years, an estimated 64% of patients receiving the Imfinzi regimen remained alive and event-free, compared with 45% in the comparator group.

For the key secondary endpoint of overall survival, the Imfinzi plus enfortumab vedotin regimen cut the risk of death by 42% relative to the comparator arm, corresponding to an overall survival hazard ratio of 0.58. Estimated median overall survival had not been reached in either arm at the time of analysis, with 78% of patients in the Imfinzi arm alive at two years versus 69% in the comparator arm.

Safety and tolerability profile

The safety and tolerability of Imfinzi plus enfortumab vedotin in the VOLGA trial were consistent with the known profiles of the individual medicines. No new safety signals were identified with the perioperative combination regimen.

Grade 3 and 4 adverse events from any cause occurred in 64% of patients receiving the Imfinzi combination and 44% of those in the comparator arm. Patient-reported quality of life was maintained after surgery among patients treated with the Imfinzi-based regimen.

Position of Imfinzi in bladder cancer treatment

This approval is AstraZeneca’s third bladder cancer indication for Imfinzi in two years and strengthens its role as an immunotherapy backbone across muscle-invasive and non-muscle-invasive disease. Imfinzi is already approved in combination with Bacillus Calmette-Guérin for BCG-naïve, high-risk non-muscle-invasive bladder cancer.

In addition, Imfinzi is approved in over 50 countries for cisplatin-eligible muscle-invasive bladder cancer based on the NIAGARA Phase III trial. The new FDA decision extends Imfinzi’s perioperative use to patients who are not candidates for cisplatin-based chemotherapy, widening access to immunotherapy-based treatment in this setting.

Key Takeaways

  • 01The FDA has introduced a new perioperative standard option for cisplatin‑ineligible muscle‑invasive bladder cancer built on Imfinzi plus enfortumab vedotin.
  • 02Robust VOLGA data, including large relative reductions in both event risk and mortality, underpinned the regulatory decision.
  • 03Safety outcomes align with existing knowledge of Imfinzi and enfortumab vedotin, supporting real-world use without new safety concerns.

FDA clears new Imfinzi bladder cancer use | Trading Dashboard